Basics of Photodynamic Therapy for Malignant Brain Tumors

DOI Web Site 16 References
  • Yamamoto Tetsuya
    Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
  • Kozuki Hidehiro
    Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
  • Tsurubuchi Takao
    Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
  • Matsuda Masahide
    Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
  • Akutsu Hiroyoshi
    Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
  • Ishikawa Eiichi
    Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
  • Takano Shingo
    Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
  • Matsumura Akira
    Department of Neurosurgery, Faculty of Medicine, University of Tsukuba

Bibliographic Information

Other Title
  • 悪性脳腫瘍に対する光線力学的療法 (PDT) の基礎

Search this article

Description

<p>  Photodynamic therapy (PDT) for primary malignant brain tumors has now been approved for coverage under Japanese national health insurance. In this therapy, talaporfin sodium (Laserphyrin®) is used as a photosensitizer to be used along with an exclusively developed laser beam source. PDT is a tumor-selective, bimodal treatment, that is based on various photodynamic reactions involving molecular oxygen and oxygenated products, which are harmful for tumor tissue. After administration, the photosensitizer is accumulated and localized in the tumor tissue, which is then exposed to a laser beam with a wavelength appropriate for absorption by the sensitizer, providing photodynamic reactions. The treatment rationale, characteristics of talaporfin sodium and the laser source used for PDT of malignant brain tumors are also described.</p>

Journal

References(16)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top